Cargando…

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive non-Hodgkin's lymphoma of indolent type (NHL), previously treated with chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blackhall, F H, Ranson, M, Radford, J A, Hancock, B W, Soukop, M, McGown, A T, Robbins, A, Halbert, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363763/ https://www.ncbi.nlm.nih.gov/pubmed/11263437 http://dx.doi.org/10.1054/bjoc.2000.1624

Ejemplares similares

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
por: Clamp, A R, et al.
Publicado: (2003)

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
por: Prendiville, J., et al.
Publicado: (1993)

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
por: Jayson, G. C., et al.
Publicado: (1995)

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.
por: McGown, A. T., et al.
Publicado: (1998)

Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours
por: Cheeseman, S L, et al.
Publicado: (2000)

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
por: Woll, P. J., et al.
Publicado: (1995)

Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
por: Prendiville, J., et al.
Publicado: (1994)

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
por: Madhusudan, S, et al.
Publicado: (2003)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro
por: Booth, C, et al.
Publicado: (1999)

Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li–Fraumeni syndrome
por: Burt, E C, et al.
Publicado: (1999)

Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.
por: Hickish, T. F., et al.
Publicado: (1991)

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial
por: Hancock, B W, et al.
Publicado: (2001)

Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
por: Rubens, R. D., et al.
Publicado: (1991)

005 OP: ENTREPRENEURIALISM, ADAPTATION, AND DISCRETION AMONG NURSES IN A TRANSNATIONAL COLLABORATION IN MALAWI AND TANZANIA
por: McGown, M
Publicado: (2017)

“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
por: DeChristopher, Brian A., et al.
Publicado: (2012)

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials
por: Nelson, Thomas J., et al.
Publicado: (2017)

Alcohol consumption and non-Hodgkin lymphoma in a cohort of older women
por: Chiu, B C-H, et al.
Publicado: (1999)

Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012)

Munc13 Is a Molecular Target of Bryostatin 1
por: Blanco, Francisco A., et al.
Publicado: (2019)

The outcome of older adults with classic Hodgkin lymphoma in British Columbia
por: Cheng, Phoebe T. M., et al.
Publicado: (2022)

Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry
por: Gurney, K A, et al.
Publicado: (1999)

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
por: Radford, J. A., et al.
Publicado: (1994)

Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification
por: Baars, J W, et al.
Publicado: (1999)

HLA Class II Defects in Burkitt Lymphoma: Bryostatin-1-Induced 17 kDa Protein Restores CD4+ T-Cell Recognition
por: Hossain, Azim, et al.
Publicado: (2011)

Interaction of the novel agent amphethinile with tubulin.
por: McGown, A. T., et al.
Publicado: (1989)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

Non-Hodgkin's Lymphoma: CME Lecture
por: Hancock, Barry W
Publicado: (1995)

Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia
por: Brennan, P, et al.
Publicado: (2000)

Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
por: Vacca, A, et al.
Publicado: (1999)

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma
por: Rohatiner, A, et al.
Publicado: (2001)

Bryostatin-1: a promising compound for neurological disorders
por: Tian, Zhen, et al.
Publicado: (2023)

Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes
por: Taylor, G M, et al.
Publicado: (1999)

Novel heterozygous deletion in the HNF1β gene - adolescent with antibody negative diabetes, longstanding hyperglycaemia without ketosis, cataracts, small echogenic kidneys with a cortical cyst, pancreatic atrophy, exocrine pancreatic insufficiency and a uterine anomaly
por: Conwell, Louise S, et al.
Publicado: (2015)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
por: Messori, A, et al.
Publicado: (2001)

Hodgkins disease
por: Ferme, C, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_56l9op7hdgc6g6fc8nc8oegfvc